Metabolic Optimization · Reviewed by Ian K. Tseng, MD

What Is Tesamorelin? A Longer-Acting GHRH Analog

Tesamorelin sits in the same mechanistic family as sermorelin — both are growth-hormone-releasing hormone analogs — but differs in two ways worth understanding: a structural modification that extends its stability, and an FDA-approved indication that most compounds in this space do not have.

Published August 4, 2026 · Medical review by Ian K. Tseng, MD, Medical Director

Soothe IV Med Spa branded amber pharmacy vial on warm marble, representing the metabolic optimization category of physician-supervised peptide therapy

The short answer

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone, structurally stabilized by a trans-3-hexenoyl group attached to the GHRH molecule. Like sermorelin, it stimulates the pituitary to release the body's own growth hormone rather than supplying growth hormone directly. Unlike most compounds discussed in this category, it holds an FDA approval — for reduction of excess visceral abdominal fat in a specific patient population.

The structural difference from sermorelin

Sermorelin is the first 29 amino acids of natural GHRH — the minimal fragment retaining activity. Tesamorelin is based on the full GHRH sequence with a trans-3-hexenoyl group attached, a modification that increases resistance to enzymatic degradation.

Practically, that means a longer duration of action. Both compounds work through the same receptor and the same upstream mechanism: prompt the pituitary, preserve the feedback loop, retain the pulsatile release pattern. The difference is stability, and therefore dosing profile.

If the GHRH mechanism itself is unfamiliar, our sermorelin explainer walks through how prompting release differs from injecting growth hormone directly.

The FDA-approved indication, stated precisely

Tesamorelin is FDA-approved for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That is the approved indication, and stating it precisely matters.

An FDA approval is specific to an indication and a population — it is not a general endorsement of a molecule for any purpose. The approval means this compound was studied in that population, for that outcome, and met the regulatory standard. Whether tesamorelin is appropriate for a patient outside that indication is a clinical judgment a physician makes individually, and prescribing outside an approved indication is a recognized part of medical practice with its own considerations.

What the visceral fat research examined

The clinical research supporting the approval measured visceral adipose tissue — the metabolically active fat surrounding the abdominal organs, distinct from subcutaneous fat under the skin. Visceral adiposity is of clinical interest because it associates with metabolic and cardiovascular risk in ways that subcutaneous fat does not to the same degree.

Measured outcomes in those trials were imaging-based assessments of visceral adipose tissue alongside metabolic markers. As with all therapy in this category, individual results vary, and research findings in one studied population do not automatically transfer to another.

Monitoring the growth hormone axis

Because tesamorelin acts on the GH axis, the monitoring parallels sermorelin. Baseline IGF-1 is required — it is the practical readout of GH activity, since growth hormone itself is released in pulses and resists single-draw interpretation. IGF-1 is retested during therapy.

Growth hormone reduces insulin sensitivity, so fasting glucose and insulin are reviewed at baseline and monitored. A physician also evaluates thyroid function and general metabolic markers. Active malignancy is a contraindication, given the growth-promoting nature of the GH/IGF-1 axis. Our bloodwork explainer covers the full panel.

Frequently asked questions

How is tesamorelin different from sermorelin?

Both are GHRH analogs that prompt the pituitary to release the body's own growth hormone rather than supplying it directly. Sermorelin is the first 29 amino acids of natural GHRH. Tesamorelin is based on the full GHRH sequence with a trans-3-hexenoyl group attached, which increases resistance to enzymatic breakdown and extends its duration of action. Tesamorelin also holds an FDA-approved indication that sermorelin does not.

What is tesamorelin FDA approved for?

Reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. An FDA approval is specific to an indication and population — it means the compound was studied for that outcome in that group and met the regulatory standard. Whether it is appropriate outside that indication is an individual clinical judgment.

What is visceral fat and why is it measured separately?

Visceral adipose tissue is the metabolically active fat surrounding the abdominal organs, distinct from subcutaneous fat beneath the skin. It is measured separately because visceral adiposity associates with metabolic and cardiovascular risk differently than subcutaneous fat does. The trials supporting tesamorelin's approval used imaging-based assessment of visceral adipose tissue.

What monitoring does tesamorelin require?

Baseline and follow-up IGF-1, since growth hormone is released in pulses and IGF-1 provides the stable readout of GH activity. Fasting glucose and insulin are monitored because growth hormone reduces insulin sensitivity. Thyroid function and general metabolic markers are also reviewed. Active malignancy is a contraindication.

Clinical references

Medically reviewed by Ian K. Tseng, MD, Medical Director of Soothe IV's peptide therapy program. The clinical statements in this article are supported by the following sources:

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007. pubmed.ncbi.nlm.nih.gov
Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Hormone & IGF Research. 2015. pmc.ncbi.nlm.nih.gov
U.S. Food & Drug Administration. Human Drug Compounding. www.fda.gov

Ready to talk to a physician?

Start your $50 Application — the comprehensive intake, physician Good Faith Examination, and medical clearance. A physician reviews your goals and labs and tells you honestly whether therapy is appropriate. Your fee credits in full toward your first month of membership. Available nationwide.

Book & Pay for Your $50 Application

Serving Orange County, Los Angeles, and San Diego — plus nationwide telehealth. All service areas.

This article is educational and is not medical advice. Statements have not been evaluated by the FDA. Peptide therapy is a physician-supervised medical service; specific protocols are determined individually after a Good Faith Examination and bloodwork, and not all applicants qualify. Some compounded medications used in physician-prescribed protocols are not FDA-approved. Data from clinical trials on FDA-approved medications should not be used to make assessments related to compounded medications. Soothe IV's peptide program is available nationwide via telehealth; prescriptions are issued by physicians licensed in your state.